Title
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Top Lab Tests For Patients With A Family History of Prostate Cancer

Why This Was Updated?

Our specialists regularly review advancements in health and wellness, ensuring our articles are updated with the newest information as it becomes accessible.
Medically Reviewed by

Early detection of prostate health concerns can make a significant difference, particularly for individuals with a family history of prostate cancer. Knowing your risk can make a significant difference, as identifying any concerns early can lead to more effective treatment.

Certain lab tests may offer valuable insights into prostate health for individuals at higher risk. These tests offer valuable insights into prostate health and help identify potential issues. By taking a preventive approach, individuals can better manage their health.

This article will guide both patients and healthcare providers through the essential lab tests for monitoring prostate cancer risk in individuals with a family history. It will explore the different tests available, their importance, and how they can support individuals in managing their health.

Sign Up to Order Labs for Your Patients With a Family History of Prostate Cancer

[signup]

Understanding Prostate Cancer Risk in Individuals with Family History

For individuals with a family history of prostate cancer, understanding their potential risk factors can support proactive healthcare choices.

Genetic Predisposition

Family history is a significant factor in determining an individual's risk for prostate cancer.

The likelihood of being at a higher risk for prostate cancer increases significantly if a close relative, such as a father or brother, has been affected. According to the American Cancer Society, the risk is particularly high for men with a brother who has the disease.

Genetic factors also play a significant role. BRCA1 and BRCA2 gene mutations, typically associated with breast and ovarian cancers, have also been associated with an increased likelihood of prostate cancer in men.

Studies suggest that prostate cancer can be inherited in an autosomal dominant pattern, where inheriting a single copy of the mutated gene from an affected parent is enough to raise the risk in their offspring.

Additional research has identified other common genetic markers associated with prostate cancer risk, such as HOXB13.

Early Detection Imperatives

Prostate cancer typically develops slowly and often does not show symptoms until advanced stages. However, high-risk factors like a family history or genetic mutations significantly raise the chances of developing the disease.

For high-risk individuals, earlier screening (typically around age 45) may support early detection of prostate health concerns, allowing healthcare providers to make timely recommendations. Regular monitoring empowers individuals to actively manage their health and alleviates anxiety about their risk.

The Role of Lab Testing in Prostate Cancer Detection

Lab testing plays a supportive role in monitoring prostate health, especially for individuals with elevated risk factors.

Why Lab Testing Matters for High-Risk Patients

For high-risk patients, lab testing can be helpful for monitoring prostate health over time, contributing to more informed health assessments. Identifying the disease earlier increases treatment options and is linked to better outcomes and higher survival rates.

How Lab Tests Complement Imaging and Biopsies

Using lab tests in combination with imaging and biopsies creates a more complete picture of prostate health. This multifaceted approach helps avoid misdiagnosis and allows for informed treatment decisions. 

For example, doctors can opt for monitoring rather than immediate invasive procedures if a PSA test indicates elevated levels but imaging shows no significant concerns.

Top Lab Tests for Patients with a Family History of Prostate Cancer

Understanding the key lab tests available for individuals with a family history of prostate cancer is essential for effective monitoring and early detection.

Prostate-Specific Antigen (PSA) Test

PSA is a protein made by prostate cells. The PSA test measures the level of PSA in the blood. This test is typically the first step in screening for prostate cancer.

In the past, a PSA level of 4.0 ng/mL typically prompted additional testing, like a prostate biopsy. However, now, healthcare providers consider other factors besides PSA levels, such as overall health, personal health history, and family medical history.

Accurately interpreting PSA levels is particularly important for high-risk individuals, as they can vary based on age and other factors

Family history influences PSA screening recommendations, often suggesting earlier and more frequent testing. Monitoring changes in PSA levels over time is essential, as a rising level within the normal range may require further evaluation.

[42

Free PSA Test

The free PSA test measures the level of PSA that is unbound to proteins in the blood. Men with prostate cancer typically exhibit a lower percentage of free PSA.

It provides additional information that can help differentiate between benign conditions, such as benign prostatic hyperplasia (BPH), and prostate cancer. Free PSA testing is often used when total PSA levels are elevated, helping doctors make more informed decisions about the need for further testing, such as biopsies.

PCA3 Urine Test

PCA3, or Prostate Cancer Antigen 3, is an overexpressed gene in prostate cancer cells. The PCA3 test analyzes this specific gene in urine samples. A higher PCA3 score indicates a greater likelihood of cancer presence.

Unlike the PSA test, which can be elevated for various reasons, the PCA3 test is more specific to prostate cancer, making it a potentially useful tool in the overall assessment process. PCA3 testing can be particularly beneficial for patients with a history of negative biopsies but chronically elevated PSA levels.

Genetic Testing for BRCA1 and BRCA2

Genetic testing for BRCA1 and BRCA2 detects mutations in these genes, which are associated with a higher risk of prostate cancer. The test can be performed as a simple blood test, a saliva sample, or a cheek swab.

Positive results may indicate a higher likelihood of being at risk for prostate cancer, which can support more personalized health planning. The results of BRCA testing can personalize risk assessment and screening protocols, prompting earlier or more frequent screenings for high-risk individuals.

4Kscore Test

The 4Kscore test measures four prostate-specific biomarkers to predict the likelihood of aggressive prostate cancer. They include:

The test provides a score from 0 to 100, with higher scores indicating an increased risk level that may warrant additional evaluation.

The 4Kscore test is recommended for men with a family history of prostate cancer or elevated PSA levels who are uncertain about needing a biopsy.

It is especially valuable because it can distinguish between low-risk and high-risk patients, reducing the need for unnecessary biopsies in those less likely to have aggressive cancer.

PHI (Prostate Health Index)

The Prostate Health Index (PHI) combines total PSA, free PSA, and p2PSA levels to provide a more comprehensive approach to prostate health.

This helps distinguish between benign conditions, like benign prostatic hyperplasia (BPH), and aggressive prostate cancer. The PHI score reflects the likelihood of clinically significant cancer upon biopsy, which can help support informed decision-making.

The PHI test may be beneficial for high-risk individuals, such as those with a family history of prostate cancer or elevated PSA levels. A higher PHI score may prompt earlier or more frequent screenings.

Other Diagnostic Tools for Prostate Cancer Risk

While lab tests are critical in assessing prostate cancer risk, other diagnostic tools contribute to a comprehensive evaluation.

Imaging Modalities

Imaging techniques such as magnetic resonance imaging (MRI) and ultrasound are essential for visualizing the prostate and detecting abnormalities that may not be evident through blood tests alone.

MRI provides detailed images that can help identify suspicious areas within the prostate, while a transrectal ultrasound can assist in guiding biopsies by pinpointing where tissue samples should be taken. When used in conjunction with lab tests, imaging modalities can help provide a clearer picture of prostate health, especially in identifying areas that may need further evaluation.

Role of Digital Rectal Exam (DRE)

The Digital Rectal Exam (DRE) is a physical examination where a healthcare provider assesses the prostate's size, shape, and texture through the rectum. Although less advanced than imaging techniques, the DRE is valuable for detecting abnormalities, such as lumps or hard areas that may suggest cancer.

The DRE is a valuable part of the initial screening process, especially when combined with lab tests like PSA levels, as it can identify areas that may need further assessment. While it may not provide definitive results, it can indicate the need for further investigation if abnormalities are found.

When Should Patients with a Family History Start Testing?

Early detection can significantly influence treatment outcomes.

Age Recommendations for High-Risk Individuals

For high-risk individuals, especially men with a family history of prostate cancer or genetic predispositions like BRCA1 and BRCA2 mutations, earlier screening is recommended.

While most men should start discussing screening around age 50, those with a family history may need to begin as early as age 45.

The American Cancer Society suggests:

  • Men at high risk should begin screening at age 45.
  • Men with more than one first-degree relative who had prostate cancer at an early age should start screening at age 40.

Frequency of Testing

After testing, if no prostate cancer is found, future screening depends on PSA results:

  • Men with a PSA below 2.5 ng/mL may need retesting every 2 years.
  • Men with a PSA of 2.5 ng/mL or higher should be screened annually.

Even after establishing a testing schedule, reviewing the pros and cons is important as new information becomes available.

[43]

How Lab Test Results Guide Prostate Cancer Management

Lab test results help patients and healthcare providers make informed decisions about the next steps and treatment options.

Next Steps After Elevated PSA or Other Abnormal Results

When a patient receives an elevated PSA result or abnormal findings, it's important to take a careful approach to understand the cause and decide on the next steps, such as:

  1. Confirm Results: Retesting the PSA level can account for inconsistencies due to factors like infections or certain medications.
  2. Assess Symptoms: Evaluating additional symptoms, such as urinary concerns or pain, can help interpret the elevated PSA.
  3. Additional Testing: If PSA levels remain high, further tests may be needed, including imaging (MRI, ultrasound) or a biopsy.
  4. Risk Assessment: Considering risk factors like age, family history, and genetics helps guide follow-up testing.
  5. Monitoring and Follow-Up: A plan may be established for regular check-ups without immediate treatment.
  6. Consultation with Specialists: In some instances, referral to a urologist or oncologist may be necessary for further evaluation and targeted management.

Personalized Management Plans

Test results can guide treatment options for prostate cancer by providing insights into the cancer's risk level and aggressiveness. They also help monitor the effectiveness of ongoing treatments. This personalized approach ensures patients receive appropriate interventions through careful monitoring, medication, or more intensive treatments.

Genetic Counseling

Lab results may indicate a need for genetic counseling, especially if there are signs of inherited mutations or a significant family history of prostate cancer. Referring patients for genetic counseling can provide insights into their risk and the implications for family members, helping guide decisions about monitoring and preventive measures.

Patient Education and Informed Decision-Making

Patient education is essential for effective prostate cancer management.

Understanding the Importance of Regular Testing

For individuals with a family history of prostate cancer, regular testing is key to early detection. Patients should be informed about the significance of consistent screenings, including the types of tests available and their roles in monitoring prostate health. Understanding these factors helps patients to take an active role in their health.

Discussing Lab Results with Healthcare Providers

When discussing lab results related to prostate cancer, it's helpful for patients to come prepared with questions. Begin by reviewing the results, especially any elevated findings like PSA levels, to understand their significance.

Ask about these results, especially how elevated PSA levels relate to cancer risk and family history. This understanding can guide the conversation about the next steps, including further testing, treatment options, or monitoring strategies.

[signup]

Key Takeaways

  • Early Detection: Targeted lab tests can be beneficial for early detection and proactive health planning, particularly for individuals with a family history of prostate health concerns. This enables timely intervention and better treatment outcomes.
  • Understanding Risk: Recognizing risk factors, including genetic predispositions, empowers patients to manage their health proactively.
  • Take Action: Patients and healthcare providers are encouraged to prioritize timely testing and discuss lab results openly to improve health outcomes.

Frequently Asked Questions (FAQs)

Here are some frequently asked questions about prostate cancer

What are the most important lab tests for prostate cancer?

Key lab tests for prostate cancer include:

  • The Prostate-Specific Antigen (PSA) test
  • Free PSA test
  • PCA3 urine test
  • Genetic tests for BRCA1 and BRCA2

These tests help assess risk, detect abnormalities, and guide treatment decisions.

How does family history affect prostate cancer risk?

Having a family history of prostate cancer significantly increases an individual's risk. Men with affected relatives, especially first-degree relatives, may be at a greater risk of developing the disease, prompting earlier and more frequent screenings.

How often should I get tested if I have a family history of prostate cancer?

Men with a family history of prostate cancer should discuss testing schedules with their healthcare provider. Generally, they may start screening at age 45, and the frequency of tests can depend on PSA levels and other risk factors.

What do elevated PSA levels mean for high-risk individuals?

Elevated PSA levels may indicate prostate issues, including cancer, but many factors can affect these readings. Elevated levels may prompt further testing or closer monitoring for high-risk individuals, as they could signify a greater likelihood of significant disease.

When should I consider genetic testing for prostate cancer?

Genetic testing should be considered if there's a strong family history of prostate cancer or if there are signs of inherited mutations, like BRCA1 or BRCA2. Discussing family history with a trusted healthcare provider can help determine the need for testing.

The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No lab tests!
  1. 4Kscore Results. (2022). Detect Your Risk of Aggressive Prostate Cancer | 4Kscore® Test. 4kscore.com. https://4kscore.com/
  2. 4Kscore Results. (2024, June 4). PC Markers. https://www.pcmarkers.com/4kscore-results
  3. American Cancer Society. (2020, June 9). Prostate Cancer Risk Factors. Www.cancer.org. https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/risk-factors.html
  4. American Cancer Society. (2023a). American Cancer Society recommendations for prostate cancer early detection. Www.cancer.org. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html
  5. American Cancer Society. (2023b). Questions to Ask About Prostate Cancer. Cancer.org. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/talking-with-doctor.html
  6. American Cancer Society. (2023c, November 22). Can Prostate Cancer Be Found Early? Www.cancer.org. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/detection.html
  7. American Cancer Society. (2023d, November 22). Targeted Drug Therapy for Prostate Cancer. Www.cancer.org. https://www.cancer.org/cancer/types/prostate-cancer/treating/targeted-therapy.html
  8. Aschuff, J. (2024, March 22). The Evotype Model: A New Frontier in Prostate Cancer Research. Rupa Health. https://www.rupahealth.com/post/the-evotype-model-a-new-frontier-in-prostate-cancer-research
  9. Blake, K. (2023, December 15). The Power of Functional Foods in Cancer Prevention. Rupa Health. https://www.rupahealth.com/post/the-power-of-functional-foods-in-cancer-prevention
  10. BRCA Gene Mutations: Cancer Risk and Genetic Testing Fact Sheet. (2024, July 19). Cancer.gov; Cancer.gov. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#what-other-cancers-are-linked-to-inherited-harmful-changes-in-brca1-and-brca2
  11. BRCA Genetic Test: MedlinePlus Medical Test. (2020, June). Medlineplus.gov. https://medlineplus.gov/lab-tests/brca-test/
  12. Castro, E., & Eeles, R. (2012). The role of BRCA1 and BRCA2 in prostate cancer. Asian Journal of Andrology, 14(3), 409–414. https://doi.org/10.1038/aja.2011.150
  13. CDC. (2024, February 23). Symptoms of Prostate Cancer. Prostate Cancer. https://www.cdc.gov/prostate-cancer/symptoms/index.html
  14. Christie, J. (2023, November 9). The Integrative Practitioner's Guide to Prostate Health: Integrative Approaches to Prevention and Healing. Rupa Health. https://www.rupahealth.com/post/prostate-health-in-focus-integrative-approaches-to-prevention-and-healing
  15. Cloyd, J. (2023, September 13). An Integrative Medicine Approach to Bladder Leaks: Lab Testing, Nutrition, and Complementary Therapies. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-bladder-leaks-lab-testing-nutrition-and-complementary-therapies
  16. Cloyd, J. (2023, September 25). Integrative Approaches to Supporting Mental Health In Chronic Conditions. Rupa Health. https://www.rupahealth.com/post/integrative-approaches-to-supporting-mental-health-in-chronic-conditions
  17. Cloyd, J. (2024, January 12). Saw palmetto's role in hormonal balance and prostate health. Rupa Health. https://www.rupahealth.com/post/saw-palmettos-role-in-hormonal-balance-and-prostate-health
  18. Cloyd, J. (2024, January 24). The Value of Urinalysis in Functional Medicine: A Tool for Comprehensive Health Assessment. Rupa Health. https://www.rupahealth.com/post/the-value-of-urinalysis-in-functional-medicine-a-tool-for-comprehensive-health-assessment
  19. Cuzick, J., Thorat, M. A., Andriole, G., Brawley, O. W., Brown, P. H., Culig, Z., Eeles, R. A., Ford, L. G., Hamdy, F. C., Holmberg, L., Ilic, D., Key, T. J., Vecchia, C. L., Lilja, H., Marberger, M., Meyskens, F. L., Minasian, L. M., Parker, C., Parnes, H. L., & Perner, S. (2014). Prevention and early detection of prostate cancer. The Lancet Oncology, 15(11), e484–e492. https://doi.org/10.1016/s1470-2045(14)70211-6
  20. Digital Rectal Exam: Purpose, Procedure & Preparation. (2022). Cleveland Clinic. https://my.clevelandclinic.org/health/diagnostics/24212-digital-rectal-exam
  21. Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., Wiley, K. E., Isaacs, S. D., Johng, D., Wang, Y., Bizon, C., Yan, G., Gielzak, M., Partin, A. W., Shanmugam, V., Izatt, T., Sinari, S., Craig, D. W., Zheng, S. L., & Walsh, P. C. (2012). Germline Mutations in HOXB13 and Prostate-Cancer Risk. The New England Journal of Medicine, 366(2), 141–149. https://doi.org/10.1056/NEJMoa1110000
  22. Ferro, M., De Cobelli, O., Lucarelli, G., Porreca, A., Busetto, G. M., Cantiello, F., Damiano, R., Autorino, R., Musi, G., Vartolomei, M. D., Muto, M., & Terracciano, D. (2020). Beyond PSA: The Role of Prostate Health Index (phi). International Journal of Molecular Sciences, 21(4), 1184. https://doi.org/10.3390/ijms21041184
  23. Free Prostate-Specific Antigen | Rupa Health. (2020). Rupa Health. https://www.rupahealth.com/biomarkers/free-prostate-specific-antigen
  24. Genetic Testing for Prostate Cancer. (2023, April 23). Prostate Cancer Foundation. https://www.pcf.org/patient-resources/family-cancer-risk/genetic-testing-prostate-cancer/
  25. Harvard Prostate Knowledge. (2009, October). What is the difference between PSA and free PSA? - Harvard Health Blog. Harvard Health Blog. https://www.health.harvard.edu/blog/what-is-the-difference-between-psa-and-free-psa-20091001114
  26. Jain, M., & Sapra, A. (2020). Cancer Prostate Screening. Prostate Cancer Screening. https://www.ncbi.nlm.nih.gov/books/NBK556081/
  27. Le, B. V., Griffin, C. R., Loeb, S., Carvalhal, G. F., Kan, D., Baumann, N. A., & Catalona, W. J. (2010). [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study. Journal of Urology, 183(4), 1355–1359. https://doi.org/10.1016/j.juro.2009.12.056
  28. Maholy, N. (2023, February 17). A functional medicine approach to anxiety: Testing, nutrition, & supplements. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-anxiety
  29. Malani, S. (2023a, March 8). What is Integrative Oncology and How Can it Help Your Cancer Journey? Rupa Health. https://www.rupahealth.com/post/what-is-integrative-oncology-and-how-can-it-help-your-cancer-journey
  30. Malani, S. (2023b, March 23). How to Talk to Your Care Team About Integrative Oncology Therapies. Rupa Health. https://www.rupahealth.com/post/how-to-talk-to-your-care-team-about-integrative-oncology-therapies
  31. Malani, S. (2023c, April 17). An Integrative Medicine Approach to Breast Cancer Prevention. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-breast-cancer-prevention
  32. Malani, S. (2023d, May 11). Complementary and Integrative Therapies for Treatment and Recovery of Ovarian Cancer. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-therapies-for-treatment-and-recovery-of-ovarian-cancer
  33. Marks, L. S., & Bostwick, D. G. (2024). Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. Reviews in Urology, 10(3), 175. https://pmc.ncbi.nlm.nih.gov/articles/PMC2556484/
  34. Mayo Clinic. (2019a). Prostate biopsy - Mayo Clinic. Mayoclinic.org. 
  35. https://www.mayoclinic.org/tests-procedures/prostate-biopsy/about/pac-20384734
  36. Mayo Clinic. (2019b). PSA test - Mayo Clinic. Mayoclinic.org. https://www.mayoclinic.org/tests-procedures/psa-test/about/pac-20384731
  37. Mayo Clinic. (2023). Benign Prostatic Hyperplasia (BPH) - Symptoms and Causes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/benign-prostatic-hyperplasia/symptoms-causes/syc-20370087
  38. National Cancer Institute. (2011, February 2). PCA3 mRNA test. www.cancer.gov. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pca3-mrna-test
  39. National Cancer Institute. (2017, June 9). Prostate-Specific Antigen (PSA) Test - National Cancer Institute. Www.cancer.gov. https://www.cancer.gov/types/prostate/psa-fact-sheet#what-is-a-normal-psa-test-result
  40. National Cancer Institute. (2018, January 30). BRCA Mutations: Cancer Risk and Genetic Testing Fact Sheet. National Cancer Institute; Cancer.gov. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#what-are-brca1-and-brca2
  41. National Cancer Institute. (2022, March 11). Prostate-Specific Antigen (PSA) Test. National Cancer Institute; Cancer.gov. https://www.cancer.gov/types/prostate/psa-fact-sheet
  42. Noble.dana. (2023, May 17). The PSA debate. Mayo Clinic Press. https://mcpress.mayoclinic.org/healthy-aging/the-psa-debate/
  43. Osses, D., Roobol, M., & Schoots, I. (2019). Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. International Journal of Molecular Sciences, 20(7), 1637. https://doi.org/10.3390/ijms20071637
  44. Pilie, P. G., Giri, V. N., & Cooney, K. A. (2016). HOXB13 and other high penetrant genes for prostate cancer. Asian Journal of Andrology, 18(4), 530–532. https://doi.org/10.4103/1008-682X.175785
  45. Prostate Cancer FAQs Archives. (n.d.). Prostate Cancer Foundation. https://www.pcf.org/faq_category/prostate-cancer-faqs/
  46. Prostate Cancer Foundation. (2017). Prostate Cancer: What Are The Risk Factors? Prostate Cancer Foundation. https://www.pcf.org/patient-resources/family-cancer-risk/prostate-cancer-risk-factors/
  47. Prostate: Anatomy, Location, Function & Conditions. (2022, August 9). Cleveland Clinic. https://my.clevelandclinic.org/health/body/23965-prostate
  48. Quintangeli, R. (2023, October 19). Adam's Renewal at 63: Physical Therapy's Role in Alleviating Pain and Urinary Incontinence. Rupa Health. https://www.rupahealth.com/post/adams-renewal-at-63-physical-therapys-role-in-alleviating-pain-and-urinary-incontinence
  49. Saedi, M. S., Zhu, Z., Marker, K., Liu, R., Carpenter, P. M., Rittenhouse, H., & Mikolajczyk, S. D. (2001). Human kallikrein 2 (hK2), but not prostate‐specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI‐6) released from prostate carcinoma cells. International Journal of Cancer, 94(4), 558–563. https://doi.org/10.1002/ijc.1501
  50. Sanoj Punnen, Pavan, N., & Parekh, D. J. (2015). Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Reviews in Urology, 17(1), 3. https://pmc.ncbi.nlm.nih.gov/articles/PMC4444768/
  51. Tempany, C., Carroll, P., & Leapman, M. (2024, September). UpToDate. Www.uptodate.com. https://www.uptodate.com/contents/the-role-of-magnetic-resonance-imaging-in-prostate-cancer
  52. The Prostate Health Index | PCFA. (2023, November 29). Prostate Cancer Survivorship Kit. https://www.prostate.org.au/testing-and-diagnosis/psa-testing/the-prostate-health-index/
  53. Total Prostate-Specific Antigen | Rupa Health. (2020). Rupa Health. https://www.rupahealth.com/biomarkers/total-psa
  54. Transrectal Ultrasound: Purpose, Preparation & Procedure. (n.d.). Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/24518-transrectal-ultrasound
  55. Verhage, B. A. J., Baffoe-Bonnie, A. B., Baglietto, L., Smith, D. S., Bailey-Wilson, J. E., Beaty, T. H., Catalona, W. J., & Kiemeney, L. A. (2001). Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology, 57(1), 97–101. https://doi.org/10.1016/S0090-4295(00)00891-8
  56. Vickers, A., Vertosick, E. A., Sjoberg, D. D., Hamdy, F., Neal, D., Anders Bjartell, Hugosson, J., 
  57. Donovan, J. L., Villers, A., Zappala, S., & Lilja, H. (2018). Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. The Journal of Urology, 199(6), 1470–1474. https://doi.org/10.1016/j.juro.2018.01.070
  58. Villanueva Herrero, J. A., Abdussalam, A., & Kasi, A. (2023, February 18). Rectal Exam. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK537356/
  59. What Does an Elevated PSA Level Mean? (n.d.). Cleveland Clinic. https://my.clevelandclinic.org/health/symptoms/15282-elevated-psa-prostate-specific-antigen-level
  60. Yoichiro Tohi, Kato, T., & Sugimoto, M. (2023). Aggressive Prostate Cancer in Patients Treated with Active Surveillance. Cancers, 15(17), 4270–4270. https://doi.org/10.3390/cancers15174270
  61. Yoshimura, H. (2023, December 27). Epigenetics and Disease Prevention: Harnessing Lifestyle Changes in Clinical Practice. Rupa Health. https://www.rupahealth.com/post/epigenetics-and-disease-prevention-harnessing-lifestyle-changes-in-clinical-practice
  62. Zhu, M., Liang, Z., Feng, T., Mai, Z., Jin, S., Wu, L., Zhou, H., Chen, Y., & Yan, W. (2023). Up-to-Date Imaging and Diagnostic Techniques for Prostate Cancer: A Literature Review. Diagnostics, 13(13), 2283. https://doi.org/10.3390/diagnostics13132283
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
See All Magazine Articles
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
National Library of Medicine
Government Authority
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
National Cancer Institute
Government Authority
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
CDC
Government Authority
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
National Institutes of Health
Government Authority
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Brain
Peer Reviewed Journal
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Chest
Peer Reviewed Journal
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source